1. Dovydenko I., Venyaminova A., Pyshnyi D., Tarassov I., Entelis N., “Modifications in Therapeutic Oligonucleotides Improving the Delivery”, in Jurga S., Erdmann V. A., Barciszewski J. (eds.), Modified Nucleic Acids in Biology and Medicine, Springer, 2016, pp. 319-337.
2. Tan W., Wang H., Chen Y., Zhang X., Zhu H., Yang C., Yang R., Liu C., “Molecular aptamers for drug delivery”, Trends in Biotechnology, 2011, vol. 29, no. 12, pp. 634-640.
3. Ginn S. L., Alexander I. E., Edelstein M. L., Abedi M. R., Wixon J., “Gene therapy clinical trials worldwide to 2012 - an update”, Journal Of Gene Medicine, 2013, vol. 15, no. 2, pp. 65-77.
4. Walther W., Stein U., “Viral Vectors for Gene Transfer”, Drugs, 2000, vol. 60, no. 2, pp. 249-271.
5. Thomas C. E., Ehrhardt A., Kay M. A., “Progress and problems with the use of viral vectors for gene therapy”, Nature Reviews Genetics, 2003, vol. 4, no. 5, pp. 346-358.
6. Kay M. A., “State-of-the-art gene-based therapies: the road ahead”, Nature Reviews Genetics, 2011, vol. 12, no. 5, pp. 316-328.
7. Oliveira C., Silveira I., Veiga F., Ribeiro A. J., “Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance”, Expert Opinion on Drug Delivery, 2015, vol. 12, no. 1, pp. 27-39.
8. Balazs D. A., Godbey W., “Liposomes for Use in Gene Delivery”, Journal of Drug Delivery, 2011, vol. 2011, pp. 1-12.
9. Dizaj S., Jafari S., Khosroushahi A., “A sight on the current nanoparticle-based gene delivery vectors”, Nanoscale Research Letters, 2014, vol. 9, no. 1, p. 252.
10. Kuo W.-T., Huang H.-Y., Huang Y.-Y., “Intracellular trafficking, metabolism and toxicity of current gene carriers”, Current Drug Metabolism, 2009, vol. 10, no. 8, pp. 885-94.
11. Raouane M., Desmaële D., Urbinati G., Massaad-Massade L., Couvreur P., “Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery”, Bioconjugate Chemistry, 2012, vol. 23, no. 6, pp. 1091-1104.
12. Grijalvo S., Ocampo S. M., Perales J. C., Eritja R., ” Synthesis of Oligonucleotides Carrying Amino Lipid Groups at the 3′-End for RNA Interference Studies”, Journal of Organic Chemistry, 2010, vol. 75, no. 20, pp. 6806-6813.
13. Grijalvo S., Ocampo S. M., Perales J. C., Eritja R., “Synthesis of Lipid-Oligonucleotide Conjugates for RNA Interference Studies”, Chemistry & Biodiversity, 2011, vol. 8, no. 2, pp. 287-299.
14. Raouane M., Desmaele D., Gilbert-Sirieix M., Gueutin C., Zouhiri F., Bourgaux C., Lepeltier E., Gref R., Ben Salah R., Clayman G., Massaad-Massade L., Couvreur P., “Synthesis, Characterization, and in Vivo Delivery of siRNA-Squalene Nanoparticles Targeting Fusion Oncogene in Papillary Thyroid Carcinoma”, Journal of Medicinal Chemistry, 2011, vol. 54, no. 12, pp. 4067-4076.
15. Nishina K., Unno T., Uno Y., Kubodera T., Kanouchi T., Mizusawa H., Yokota T., “Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol”, Molecular Therapy, 2008, vol. 16, no. 4, pp. 734-740.
16. Letsinger R. L., Zhang G. R., Sun D. K., Ikeuchi T., Sarin P. S., “Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture”, Proceedings of the National Academy of Sciences of the United States of America, 1989, vol. 86, no. 17, pp. 6553-6556.
17. Moschos S. A., Jones S. W., Perry M. M., Williams A. E., Erjefalt J. S., Turner J. J., Barnes P. J., Sproat B. S., Gait M. J., Lindsay M. A., “Lung Delivery Studies Using siRNA Conjugated to TAT(48−60) and Penetratin Reveal Peptide Induced Reduction in Gene Expression and Induction of Innate Immunity”, Bioconjugate Chemistry, 2007, vol. 18, no. 5, pp. 1450-1459.
18. Ueno Y., Kawada K., Shibata A., Yoshikawa K., Wataya Y., Kitade Y., “Synthesis and silencing properties of siRNAs possessing lipophilic groups at their 3’-termini”, Nucleic Acids Symposium Series, 2008, vol. 52, no. 1, pp. 503-504.
19. Habus I., Zhao Q., Agrawal S., “Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide-amino-beta-cyclodextrins and adamantane conjugates”, Bioconjugate Chemistry, 1995, vol. 6, no. 4, pp. 327-331.
20. Rait A., Pirollo K., Will D. W., Peyman A., Rait V., Uhlmann E., Chang E. H., “3’-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells”, Bioconjugate Chemistry, 2000, vol. 11, no. 2, pp. 153-160.
21. Reed M. W., Adams A. D., Nelson J. S., Meyer R. B., “Acridine- and cholesterol-derivatized solid supports for improved synthesis of 3’-modified oligonucleotides”, Bioconjugate Chemistry, 2010, vol. 2, no. 4, pp. 217-225.
22. Vu H., Singh P., Joyce N., Hogan M. E., Jayaraman K., “Synthesis of cholesteryl supports and phosphoramidites containing a novel peptidyl linker for automated synthesis of triple-helix forming oligonucleotides (TFOs)”, Nucleic Acids Symposium Series, 1993, no. 29, pp. 19-20.
23. Vu H., Hill T. S., Jayaraman K., “Synthesis and Properties of Cholesteryl-Modified Triple-Helix Forming Oligonucleotides Containing a Triglycyl Linker”, Bioconjugate Chemistry, 1994, vol. 5, no. 6, pp. 666-668.
24. Will D. W., Brown T., “Attachment of vitamin E derivatives to oligonucleotides during solid-phase synthesis”, Tetrahedron Letters, 1992, vol. 33, no. 19, pp. 2729-2732.
25. MacKellar C., Graham D., Will D. W., Burgess S., Brown T., “Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups”, Nucleic Acids Research, 1992, vol. 20, no. 13, pp. 3411-3417.
26. Reed M. W., Lukhtanov E. A., Gorn V. V., Lucas D. D., Zhou J. H., Pai S. B., Cheng Y. C., Meyer R. B., “Structureactivity relationships of cytotoxic cholesterol-modified DNA duplexes”, Journal of Medicinal Chemistry, 1995, vol. 38, no. 22, pp. 4587-4596.
27. Matysiak S., Frank R., Pfleiderer W., “Acetal Oligonucleotide Conjugates in Antisense Strategy”, Nucleosides and Nucleotides, 1997, vol. 16, no. 5-6, pp. 855-861.
28. Godeau G., Staedel C., Barthélémy P., “Lipid-Conjugated Oligonucleotides via “Click Chemistry” Efficiently Inhibit Hepatitis C Virus Translation”, Journal of Medicinal Chemistry, 2008, vol. 51, no. 15, pp. 4374-4376.
29. Fomich M. A., Kvach M. V., Navakouski M. J., Weise C., Baranovsky A. V., Korshun V. A., Shmanai V. V., “Azide Phosphoramidite in Direct Synthesis of Azide-Modified Oligonucleotides”, Organic Letters, 2014, vol. 16, no. 17, pp. 4590-4593.
30. Andreyev A. Y., Tsui H. S., Milne G. L., Shmanai V. V., Bekish A. V., Fomich M. A., Pham M. N., Nong Y., Murphy A. N., Clarke C. F., Shchepinov M. S., “Isotope-reinforced polyunsaturated fatty acids protect mitochondria from oxidative stress”, Free Radical Biology and Medicine, 2015, vol. 82, pp. 63-72.
31. Hill S., Lamberson C. R., Xiu L., To R., Tsui H. S., Shmanai V. V., Bekish A. V., Awad A. M., Marbois B. N., Cantor C. R., Porter N. A., Clarke C. F., Shchepinov M. S., “Small amounts of isotope-reinforced polyunsaturated fatty acids suppress lipid autoxidation”, Free Radical Biology and Medicine, 2012, vol. 53, no. 4, pp. 893-906.
32. Dussault P. H., Eary C. T., Woller K. R., “Total Synthesis of the Alkoxydioxines (+)- and (−)-Chondrillin and (+)- and (−)-Plakorin via Singlet Oxygenation/Radical Rearrangement”, Journal of Organic Chemistry, 1999, vol. 64, no. 6, pp. 1789-1797.